Latin America Peptide Therapeutics Market Size & Outlook
The peptide therapeutics market in Latin America is expected to reach a projected revenue of US$ 8,876.8 million by 2033. A compound annual growth rate of 7.8% is expected of Latin America peptide therapeutics market from 2026 to 2033.
Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health
Other key industry trends
In terms of revenue, Latin America region accounted for 3.3% of the global peptide therapeutics market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
North America is the fastest growing regional market and is projected to reach USD 199,806.7 million by 2033.
The Latin America market for peptide therapeutics has seen considerable growth, driven by a high prevalence of diseases and a surge in the demand for peptide-based medications. Countries such as Brazil and Argentina stand out as significant hubs for these drugs within the region.
Government support and collaborative research endeavors are expected to play crucial roles in fostering market development. In addition, the rising need for peptide-based drugs, influenced by the current disease landscape & strong interest from healthcare professionals, is a significant factor in market expansion.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Peptide Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Metabolic Disorders was the largest segment with a revenue share of 74.59% in 2025.
Horizon Databook has segmented the Latin America peptide therapeutics market based on gastrointestinal disorders, cancer, metabolic disorders, cardiovascular disorders, pain, respiratory disorders, infectious disease, dermatological disorders, renal disorders, neurological disorders covering the revenue growth of each sub-segment from 2021 to 2033.
The Latin America market for peptide therapeutics has seen considerable growth, driven by a high prevalence of diseases and a surge in the demand for peptide-based medications. Countries such as Brazil and Argentina stand out as significant hubs for these drugs within the region.
Government support and collaborative research endeavors are expected to play crucial roles in fostering market development. In addition, the rising need for peptide-based drugs, influenced by the current disease landscape & strong interest from healthcare professionals, is a significant factor in market expansion.
Latin America Peptide Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Metabolic disorders
Cardiovascular disorders
Respiratory disorders
Gastrointestinal disorders
Infectious disease
Pain
Dermatological disorders
Neurological disorders
Renal disorders
Others
Latin America Peptide Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2033)
Generic
Innovative
Latin America Peptide Therapeutics Market Type of Manufacturers Outlook (Revenue, USD Million , 2021-2033)
Inhouse
Outsourced
Latin America Peptide Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Parenteral Route
Oral Route
Pulmonary
Mucosal
Others
Latin America Peptide Therapeutics Market Synthesis Technology Outlook (Revenue, USD Million , 2021-2033)
Recombinant DNA Technology
Solid-Phase Peptide Synthesis (SPPS)
Hybrid
Liquid-Phase Peptide Synthesis (LPPS)
Others
Latin America Peptide Therapeutics Market Type of Manufacturer Outlook (Revenue, USD Million , 2021-2033)
Inhouse
Outsourced
Reasons to subscribe to Peptide Therapeutics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Peptide Therapeutics Market Outlook databook
Our clientele includes a mix of Peptide Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America Peptide Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Latin America Peptide Therapeutics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Latin America Peptide Therapeutics Market, 2021-2033 (US$M)